BN-104 free base · Synonyms: BNM-1192

BN-104 (BNM-1192) can inhibit the Menin-MLL interaction and can be used in cancer research, such as acute myeloid leukemia.

For research use only. Not for human or veterinary use.

Target Epigenetic Reader Domain Potassium Channel

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

BN-104 structure

CAS No.: 2938995-50-5

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
1 g	USD 1,280.00	BP-00867-1g	In stock	Get quote
5 g	Inquire	BP-00867-5g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

BN-104 (BNM-1192) can inhibit the Menin-MLL interaction and can be used in cancer research, such as acute myeloid leukemia.

Biological activity

In Vitro Zefamenib (BN-104) inhibits the proliferation of leukemia cells, with IC50 values of: MV-4-11 AF4 fusion (3.5 nM); MOLM13 AF9 fusion (12 nM); OCI-AML3 NPM1 mutant (11 nM). Zefamenib (10 μM, 0-24 h) causes degradation of Menin protein in MV-4-11 cells. In Vivo Zefamenib (BN-104) (0-60 mg/kg, oral, twice a day, 21 days) inhibits tumor proliferation in a mouse model.

Identifiers

SMILES: C(=O)(N1CCC2(CN(C2)C=3C(OC4=C(C=C(F)C=C4)C=5C(=NC=NC5)C6CC6)=NN=CN3)CC1)[C@@H]7[C@@]8([C@](CN7)(CCC8)[H])[H]
InChIKey: XDXAYPYOHXUEAM-CLHVYKLBSA-N

Specifications

MW (average): 570.6604
Formula: C₃₁H₃₅FN₈O₂
CAS No.: 2938995-50-5
Physical state: Solid
Color: white to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 3 years; 4℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1].Carbonyl substituted diazaspiro compounds and its use Assignee: BioNova Pharmaceuticals (Shanghai) Limited World Intellectual Property Organization, WO2023098876 A1

Same target

Search Epigenetic Reader Domain

Same research area

Search Cancer